Focused On-demand Library for tRNA wybutosine-synthesizing protein 2 homolog

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q53H54

UPID:

TYW2_HUMAN

Alternative names:

tRNA(Phe) (4-demethylwyosine(37)-C(7)) aminocarboxypropyltransferase

Alternative UPACC:

Q53H54; Q6PKB9; Q96F21; Q9NWK6

Background:

The tRNA wybutosine-synthesizing protein 2 homolog, also known as tRNA(Phe) (4-demethylwyosine(37)-C(7)) aminocarboxypropyltransferase, plays a crucial role in the wybutosine biosynthesis pathway. This enzyme is responsible for the transfer of the acp group from S-adenosyl-L-methionine to 4-demethylwyosine, leading to the production of wybutosine-86, a hypermodified guanosine found adjacent to the anticodon of eukaryotic phenylalanine tRNA.

Therapeutic significance:

Understanding the role of tRNA wybutosine-synthesizing protein 2 homolog could open doors to potential therapeutic strategies.